Neuroprotection Against NMDA-Induced Retinal Damage by Philanthotoxin-343 Involves Reduced Nitrosative Stress
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Neuroprotection Against NMDA-Induced Retinal Damage by Philanthotoxin-343 Involves Reduced Nitrosative Stress. / Mohamad, Mohamad Haiqal Nizar; Abu, Izuddin Fahmy; Fazel, Muhammad Fattah; Agarwal, Renu; Iezhitsa, Igor; Juliana, Norsham; Mellor, Ian R.; Franzyk, Henrik.
In: Frontiers in Pharmacology, Vol. 12, 798794, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Neuroprotection Against NMDA-Induced Retinal Damage by Philanthotoxin-343 Involves Reduced Nitrosative Stress
AU - Mohamad, Mohamad Haiqal Nizar
AU - Abu, Izuddin Fahmy
AU - Fazel, Muhammad Fattah
AU - Agarwal, Renu
AU - Iezhitsa, Igor
AU - Juliana, Norsham
AU - Mellor, Ian R.
AU - Franzyk, Henrik
N1 - Funding Information: This work was supported by funding from the Ministry of Higher Education, Malaysia under the Fundamental Research Grant Scheme (FRGS/1/2017/SKK10/UNIKL/02/1). Funding Information: The authors thank the Ministry of Higher Education (MOHE) Malaysia for the financial support provided via the Fundamental Research Grant Scheme (ref no. FRGS/1/2017/SKK10/UNIKL/ 02/1). The authors acknowledge the technical assistance provided by Mohd Aizuddin Mohd Lazaldin, Lidawani Lambuk, Azliana Ahmad Jafri and Natasha Najwa Nor Arfuzir from Centre for Neuroscience Research (NeuRon), Universiti Teknologi MARA in running the experimental procedures. Publisher Copyright: Copyright © 2021 Mohamad, Abu, Fazel, Agarwal, Iezhitsa, Juliana, Mellor and Franzyk.
PY - 2021
Y1 - 2021
N2 - N-methyl-D-aspartate receptor (NMDAR) overstimulation is known to mediate neurodegeneration, and hence represents a relevant therapeutic target for neurodegenerative disorders including glaucoma. This study examined the neuroprotective effects of philanthotoxin (PhTX)-343 against NMDA-induced retinal injury in rats. Male Sprague Dawley rats were divided into three groups; group 1 received phosphate buffer saline as the negative control, group 2 was injected with NMDA (160 nM) to induce retinal excitotoxic injury, and group 3 was pre-treated with PhTX-343 (160 nM) 24 h before NMDA exposure. All treatments were given intravitreally and bilaterally. Seven days post-treatment, rats were subjected to visual behaviour assessments using open field and colour recognition tests. Rats were then euthanized, and the retinas were harvested and subjected to haematoxylin and eosin (H&E) staining for morphometric analysis and 3-nitrotyrosine (3-NT) ELISA protocol as the nitrosative stress biomarker. PhTX-343 treatment prior to NMDA exposure improved the ability of rats to recognize visual cues and preserved visual functions (i.e., recognition of objects with different colours). Morphological examination of retinal tissues showed that the fractional ganglion cell layer thickness within the inner retina (IR) in the PhTX-343 treated group was greater by 1.28-fold as compared to NMDA-treated rats (p < 0.05) and was comparable to control rats (p > 0.05). Additionally, the number of retinal cell nuclei/100 μm2 in IR for the PhTX-343-treated group was greater by 1.82-fold compared to NMDA-treated rats (p < 0.05) and was comparable to control group (p > 0.05). PhTX-343 also reduced the retinal 3-NT levels by 1.74-fold compared to NMDA-treated rats (p < 0.05). In conclusion, PhTX-343 pretreatment protects against NMDA-induced retinal morphological changes and visual impairment by suppressing nitrosative stress as reflected by the reduced retinal 3-NT level.
AB - N-methyl-D-aspartate receptor (NMDAR) overstimulation is known to mediate neurodegeneration, and hence represents a relevant therapeutic target for neurodegenerative disorders including glaucoma. This study examined the neuroprotective effects of philanthotoxin (PhTX)-343 against NMDA-induced retinal injury in rats. Male Sprague Dawley rats were divided into three groups; group 1 received phosphate buffer saline as the negative control, group 2 was injected with NMDA (160 nM) to induce retinal excitotoxic injury, and group 3 was pre-treated with PhTX-343 (160 nM) 24 h before NMDA exposure. All treatments were given intravitreally and bilaterally. Seven days post-treatment, rats were subjected to visual behaviour assessments using open field and colour recognition tests. Rats were then euthanized, and the retinas were harvested and subjected to haematoxylin and eosin (H&E) staining for morphometric analysis and 3-nitrotyrosine (3-NT) ELISA protocol as the nitrosative stress biomarker. PhTX-343 treatment prior to NMDA exposure improved the ability of rats to recognize visual cues and preserved visual functions (i.e., recognition of objects with different colours). Morphological examination of retinal tissues showed that the fractional ganglion cell layer thickness within the inner retina (IR) in the PhTX-343 treated group was greater by 1.28-fold as compared to NMDA-treated rats (p < 0.05) and was comparable to control rats (p > 0.05). Additionally, the number of retinal cell nuclei/100 μm2 in IR for the PhTX-343-treated group was greater by 1.82-fold compared to NMDA-treated rats (p < 0.05) and was comparable to control group (p > 0.05). PhTX-343 also reduced the retinal 3-NT levels by 1.74-fold compared to NMDA-treated rats (p < 0.05). In conclusion, PhTX-343 pretreatment protects against NMDA-induced retinal morphological changes and visual impairment by suppressing nitrosative stress as reflected by the reduced retinal 3-NT level.
KW - excitotoxicity
KW - glaucoma
KW - N-methyl-D-aspartate receptor
KW - N-methyl-D-aspartate receptor overstimulation
KW - neurodegeneration
KW - philanthotoxin-343
KW - retinal ganglion cell
KW - visual behavioural analysis
U2 - 10.3389/fphar.2021.798794
DO - 10.3389/fphar.2021.798794
M3 - Journal article
C2 - 34970151
AN - SCOPUS:85121981742
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 798794
ER -
ID: 289309454